Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    Jamie Erdahl: Good Morning Football host talks to Her Huddle about the challenges and highlights from her first year in the job | NFL News

    February 2, 2023

    Shraddha Kapoor and Ananya Panday clicked in the city today

    February 2, 2023

    Bitcoin flirts with $24K as cryptos garner buyers in post-Fed rally

    February 2, 2023

    Rape charge against Man United player Greenwood dropped | Football News

    February 2, 2023
    Facebook Twitter Instagram
    • Privacy Policy
    • Contact Us
    • About Us
    • Disclaimer
    Facebook Twitter Instagram YouTube
    Legacy Medi4Legacy Medi4
    • World News
    • Business
    • Entertainment
    • Health
    • Science
    • Sports
    • Technology
    Legacy Medi4Legacy Medi4
    Home»Business»Cancer test developer Accustem seeks Nasdaq uplisting, $10M offering (OTCMKTS:ACUT)
    Business

    Cancer test developer Accustem seeks Nasdaq uplisting, $10M offering (OTCMKTS:ACUT)

    Todd LivingstonBy Todd LivingstonNovember 18, 2022No Comments1 Min Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The first to provide a hologram, a night panoramic view of the city of Bangkok.  A financial center for multinational companies in Asia.  The idea of ​​increasing growth is the IPO strategy.  Double exposure.

    Pictures are 2d images

    Oncology startup Accustem Sciences (OTCQB: ACUT) has filed to list its shares on the Nasdaq and raised $10M in a public offering.

    Accustem did not mention in writing the number and value of they share what they want to offer, but it’s reflected in the pay list they look at raise about $10M.

    The diagnostics company’s shares are currently traded OTC under the symbol ACUT. The company hopes to list it on the Nasdaq under the same symbol.

    The company added that it may redivide shares before the deal. Think Equity is working on a book guide.

    Based in New York, Accustem’s lead product, StemPrint ER, is used to predict the risk of distant recurrence in ER+ HER2- breast cancer patients. The company said it plans to launch the product after establishing a commercial lab and obtaining US regulatory approval for testing, a process it expects to take 18 months.

    With no products in the market, Accustem has been operating in the red. For nine months ended Sept. 30, Accustem reported a net loss of $2.8M without cash.

    In September, Accustem announced that it had received US approval for its StemPrint ER test.

    Source link

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Todd Livingston

    Related Posts

    Bitcoin flirts with $24K as cryptos garner buyers in post-Fed rally

    February 2, 2023

    Lilly’s quarterly results impacted by less than expected growth in diabetes drug Mounjaro

    February 2, 2023

    TeraWulf latest bitcoin miner to restructure debt, stock dives (NASDAQ:WULF)

    February 2, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Jamie Erdahl: Good Morning Football host talks to Her Huddle about the challenges and highlights from her first year in the job | NFL News

    February 2, 2023

    Shraddha Kapoor and Ananya Panday clicked in the city today

    February 2, 2023

    Bitcoin flirts with $24K as cryptos garner buyers in post-Fed rally

    February 2, 2023

    Rape charge against Man United player Greenwood dropped | Football News

    February 2, 2023

    Subscribe to Updates

    Get the latest news from Legacy Medi4!

    Our Picks

    Jamie Erdahl: Good Morning Football host talks to Her Huddle about the challenges and highlights from her first year in the job | NFL News

    February 2, 2023

    Shraddha Kapoor and Ananya Panday clicked in the city today

    February 2, 2023

    Bitcoin flirts with $24K as cryptos garner buyers in post-Fed rally

    February 2, 2023

    Type above and press Enter to search. Press Esc to cancel.